CPIX - Cumberland Pharmaceuticals Inc.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
19%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 5.82%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -7.98%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.25
Debt Ratio is 0.59
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations Growth is 0.89%
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cumberland Pharmaceuticals Inc. (CPIX) - cumberlandpharma.com
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO -
Employees - 99
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.